home All News open_in_new Full Article

Indegene Bets Big On Precision Pharma Marketing With $104 Million BioPharm Acquisition Says ICICI Securities

ICICI Securities maintains 'Add' rating on Indegene as it sees BioPharm acquisition to strengthen its presence in brand activation.


today 11 h. ago attach_file Economics

attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Politics


ID: 279266710
Add Watch Country

arrow_drop_down